CVS Health Allergy Relief D Tablets Recalled for Failed Dissolution
CVS Health Allergy Relief D Extended Release Tablets are being recalled because they failed to meet dissolution specifications. The recall affects 41,784 boxes distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. Failed dissolution specifications constitute a labeling/manufacturing defect with potential efficacy concerns but no documented harm, meeting the criteria for Moderate severity.
Plain-English summary
CVS Health Allergy Relief D, containing Fexofenadine HCl 60mg (antihistamine) and Pseudoephedrine HCl 120mg (nasal decongestant), is being recalled due to failed dissolution specifications. The product is supplied in two configurations: 20-count boxes (UPC 050428436189) and 30-count boxes (UPC 050428290538).
The recall affects approximately 41,784 boxes that were distributed nationwide in the USA. The affected lot numbers are: for 20-count boxes, AC2000968A and AC2000968F (expiration 8/31/2022); for 30-count boxes, 79C002624B (expiration 4/30/2022), AC2103330G, and AC2103330H (expiration 1/31/2023). The product was manufactured by Dr. Reddy's Laboratories, Inc. in India and distributed by CVS Pharmacy Inc.
Consumers who have purchased this product should stop using it. Those with questions or concerns should contact their healthcare provider or pharmacist.
The recalled product
- Product
- CVS Health, Allergy Relief D, Fexofenadine HCl 60mg/Antihistamine Pseudoephedrine HCl 120mg/Nasal Decongestant, a) 20 Extended Release Tablets per box, UPC 050428436189, b) 30 Extended Release Tablets per box, UPC 050428290538, Distributed by CVS Pharmacy Inc., One CVS Drive, Wo
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Hazard
- dissolution-failure
- efficacy-concern
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #s: a) (20-count): AC2000968A
- AC2000968F
- Exp. 8/31/2022. b) (30-count): 79C002624B
- Exp. 4/30/2022
- AC2103330G
- AC2103330H
- Exp. 1/31/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27